



Express Mail No. EV620759715US

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if known	
		Application Number	10/070,587
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	March 8, 2002
		First Named Inventor	Leszek Wojnowski
		Art Unit	1642
		Examiner Name	Brandon J. Fetterolf
		Attorney Docket Number	VOS-30
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ¹ - Number ² - Kind Code ³				
		WO 99/13106	03/18/1999	PCT		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T ⁶
		BEAUNE et al., "Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase", <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 83:8064-8068 (1986).	
		EISELT et al., "Identification and functional characterization of eight CYP3A4 protein variants", <i>Pharmacogenetics</i> , 11:447-458 (2001).	
		HASHIMOTO et al., "Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control", <i>European journal of biochemistry / FEBS</i> , 218:585-595 (1993).	
		WANG et al., "Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms", <i>Drug Metabolism and Disposition</i> , 27(2):167-172 (1999).	
		WESTLIND et al., "Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5'-Upstream Regulatory Region", <i>Biochemical and Biophysical Research Communications</i> , 259:201-205 (1999).	
		EMBL-Bank Accession No. A1638117, "ts50e10.x1 NCI CGAP_Ut1 Homo sapiens cDNA clone IMAGE:2232042 3' similar to gb:J04182 LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN 1 PRECURSOR (HUMAN);, mRNA sequence."	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.